Address: 2405 North Fraser Street
                    Georgetown, SC 29442
     Phone:    (843) 545-5600

     Visit the Georgetown Hospital System website

     Get directions to Georgetown Hospital System

Participation in the following CTN Cooperative Group studies:

CTO #100899 - NSABP B-39: Breast Program
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs. Partial Breast Irradiation (PBI) for Women with Stage 0,I, or II Breast Cancer

CTO #101183 - NSABP B-40: Breast Program
A Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect in Pathologic Complete Response (pCD) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimes

CTO #101171 - Tailor-x PACCT-1: Breast Program
Program for the Assistance of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The Tailor-X Trial

CTO #101184 - ECOG 5204: Gastrointestinal Program
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin Vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pro-operative Chemoradiation

CTO #101185 - ECOG 5202: Gastorintestinal Program
A Randomized Phase III Study Comparing 5-FU, Leucovorin, and Oxaliplatin Vs. 5-FU, Leucovorin, Oxaliplatin, and Bevacizumab in Patients with Stage II Colon Cancer at High Risk to Determine Prospectively to Prognostic value of Molecular Markers

CTO #101186 - CALGB C80405: Gastrointestinal Program
A Phase II Trial of Irinotecan, 5FU, Leucovorin or Oxaliplatin, 5FU, Leucovorin with Bevacizumab or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Color or Rectum